Outstanding problems with response evaluation criteria in solid tumors (RECIST) in breast cancer

被引：25

作者：

Kimura M. ^{[1
]}

Tominaga T. ^{[2
]}

机构：

[1] Department of Surgery, Gunma Cancer Center, Ota 373-8550, 617-1, Takabayashi-nishimachi

[2] Breasl Cancer Center, Toyosu Hospital, Showa University

来源：

Breast Cancer | 2002年 / 9卷 / 2期

关键词：

Breast cancer; RECIST;

D O I：

10.1007/BF02967580

中图分类号：

学科分类号：

摘要：

Background: In 1999 European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States and National Cancer Institute of Canada published Response Evaluation Criteria in Solid Tumors (RECIST) as a revision of the WHO criteria to achieve a unified, objective set of criteria for assessing antitumor activity. The present paper discusses breast cancer assessment using RECIST and discusses various outstanding problems in breast cancer therapy. Methods: The subjects were 50 advanced/recurrent breast cancer patients who were eligible/completed cases and were registered in various clinical trials at Gunma Cancer Center from 1995-2000. The subjects were investigated with regard to the application of RECIST to evaluate the appropriateness and efficacy of the criteria for these patients, in comparison with General Rules for Clinical and Pathological Recording of Breast Cancer formulated by the Japanese Breast Cancer Society (JBCS). In addition, a study was conducted of the survival rate as a function of the initial site of metastasis in 258 recurrent cases. Results: Of the 50 cases judged to be eligible by the JBCS General Rules, 16 cases (32%) were judged to be ineligible by RECIST. The results using the two sets of criteria were the same for CR and PD, while there were some differences in PR and SD/NC. Conclusion: To fully adopt RECIST for breast cancer, the following should be discussed further: (1) the exclusion of bone lesions (2) assessment of long NC (3) difference in survival by metastatic lesion site (4) eligible cases are reduced due to the exclusion of target lesions having a diameter of less than 2.0 cm.

引用

页码：153 / 159

页数：6

共 9 条

[1]

Miller A.B., Hoogstraten B., Staquet M., Winkler A., Reporting results of cancer treatment, Cancer, 47, 1, pp. 207-214, (1981)

[2]

Revised Version of the WHO Criteria Published in the WHO Handbook for Reporting Results of Cancer Treatment, (1999)

[3]

The Japanese Breast Cancer Society: General Rules for Clinical and Pathological Recording of Breast Cancer, pp. 58-68, (2000)

[4]

Therasse P., Arbuck S.G., Eisenhauer E.A., Wanders J., Kaplan R.S., Rubinstein L., Verweij J., Van Glabbeke M., Van Oosterom A.T., Christian M.C., Gwyther S.G., New guidelines to evaluate the response to treatment in solid tumors, Journal of the National Cancer Institute, 92, 3, pp. 205-216, (2000)

[5]

Warr D., McKinney S., Tannock I., Influence of measurement error on assessment of response to anticancer chemotherapy: Proposal for new criteria of tumor response, Journal of Clinical Oncology, 2, 9, pp. 1040-1046, (1984)

[6]

James K., Eisenhauer E., Christian M., Terenziani M., Vena D., Muldal A., Therasse P., Measuring response in solid tumors: Unidimensional versus bidimensional measurement, Journal of the National Cancer Institute, 91, 6, pp. 523-528, (1999)

[7]

Gehan E.A., Tefft M.C., Will there be resistance to the RECIST (response evaluation criteria in solid tumors)?, Journal of the National Cancer Institute, 92, 3, pp. 179-181, (2000)

[8]

Robertson J.F.R., Howell A., Buzdar A., Von Euler M., Lee D., Static disease on anastrozole provides similar benefit as objective response in patients with advanced breast cancer, Breast Cancer Research and Treatment, 58, 2, pp. 157-162, (1999)

[9]

Takahashi Y., Survival without tumor shrinkage: Reevaluation of survival gain by cytostatic effect of chemotherapy, J Natl Cancer Inst, 87, (1995)

← 1 →